Monitoring Desk:
A medicine that may treat and prevent Covid-19 is now being tested in patients in multiple sites around the United States, according to an announcement Thursday from Regeneron Pharmaceuticals Inc.
It is the first trial of a Covid-19 antibody cocktail in the United States. If successful, Regeneron hopes it could be available by the fall.
The clinical trial started Wednesday. Regeneron said its antibody cocktail will be tested in four separate study populations: people who are hospitalized with Covid-19; people who have symptoms for the disease, but are not hospitalized; people who are healthy but are at a high risk for getting sick; and healthy people who have come into close contact with a person who is sick.
“We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral ‘escape,’ a critical precaution in the midst of an ongoing global pandemic,” Dr. George Yancopoulos, co-founder, president and chief scientific officer at Regeneron, said in a press release. “Ultimately, the world needs multiple solutions, and the innovative biopharma industry is collectively working hard to help as many people as possible with a variety of complementary approaches.”
Courtesy: CNN
